CINC / CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from Ast more_horizontal

AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline more_horizontal

AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to st more_horizontal

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint. more_horizontal

Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed t more_horizontal

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the follo more_horizontal

CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treat more_horizontal

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its le more_horizontal